has moved!

Brava Diagnostics has merged with MBio Diagnostics. Please visit to see the latest news.


Welcome to Brava Diagnostics

Brava Diagnostics is developing a portfolio of point-of-care tests for medical settings where lab-quality results are vital in making time-critical decisions. We have active product development programs in COVID-19, host-response biomarkers and cardiac markers.

The features of the LightDeck® platform were designed to meet customer requirements:

  • Quality: Highly sensitive tests that deliver lab-quality results
  • Quick: Actionable data in 5-15 minutes with a simple procedure
  • Quantitative: More data to inform treatment decisions
  • Multiplex: Multiple related tests for better precision plus internal quality control to maximize safety

Cardiac Markers

Among our first products will be a NextGen test for heart attack: a high-sensitivity troponin test for the emergency department.


Host-response biomarkers signal “out of control” immune response in acute infection. Brava tests will help stage patients.


The Brava COVID-19 Antibody Panel is to determine exposure to the SARS-CoV-2 virus and potential immunity.

The LightDeck Platform

The LightDeck platform consists of a robust, portable fluorescence analyzer and disposable, multiplex test cartridges. The test procedure is simple, so that an untrained user can perform testing at the point-of-care. Each cartridge contains at least 16 discreet analysis zones that enables replicate measurements for improved performance. Panels can be configured to run   multiple related tests simultaneously to help diagnosis or rule-out a specific condition. Internal quality control runs with every test to ensure quality and safety.

Leadership Team

The Brava founders are veterans of the diagnostics industry.

Byron Hewett

Chief Executive Officer

David Okrongly, PhD

Chief Operating Officer

Carrie Mulherin

Chief Marketing Officer

Download our Fact Sheet

Download a 2-page strategy summary.

Schedule a meeting

Let's talk!